Tvardi Therapeutics Inc Share Price (NASDAQ: TVRD)

Tvardi Therapeutics Inc Stock Performance

as on October 15, 2025 at 1:29 am IST

Day's Low
Day's High
$6.15
Day's Price Range
$7.12
$6.94
11.38%
Downside
2.59%
Upside
52 Week's Low
52 Week's High
$5.65
52-Week Price Range
$43.65
$6.94
18.59%
Downside
528.96%
Upside

Tvardi Therapeutics Inc share price movements today

Previous Close: $6.69
Open: $6.65
Volume: 1.8M
Day's Low - High: $6.15 - $7.12
52 Week Low - High: $5.65 - $43.65

Tvardi Therapeutics Inc Historical Returns

1 Month Return: -79.27 %
3 Month Return: -73.19 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Tvardi Therapeutics Inc Stock Fundamentals & Key Indicators

Check Tvardi Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$242.3M

EPS (TTM)

-1.9

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

2887600.00%

Tvardi Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tvardi Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Tvardi Therapeutics Inc	NA	$242.3M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.9B	226.08%	-505.15	-12.96%
Beone Medicines Ltd	NA	$37.1B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$104.4B	91.48%	28.99	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.1B	-2.15%	14.07	31.37%

Tvardi Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Tvardi Therapeutics Inc Stock has increased by 195% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 15, 2025 to October 15, 2025

Change:195% versus previous 30 day period

Tvardi Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	4	3	2	0	2	1	2	-
Gross Profit	3	2	1	0	2	1	2	0
Operating Income	-28	-4	-29	-16	-6	-6	-2	-8
EBITDA	-27	-3	-28	-18	-10	-5	-2	-8
Interest Expense	-	-	1	1	1	2	2	-
Depreciation	-	0	0	0	0	-	-	0
Income Before Tax	-28	-4	-30	-20	-12	-8	-4	4
Income Tax Expense	-	-	-	-	-	0	-	-
Net Income	-28	-4	-30	-20	-12	-7	-4	4
Net Profit Margin	-576.08%	-144.84%	-1437.75%	-2019.78%	-488.11%	-527.77%	-190.97%	0.00%

Tvardi Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	135	23	41	20	7
Gross Profit	-	21	34	14	6
Operating Income	5	-89	-21	-18	-55
EBITDA	8	-86	-20	-17	-62
Interest Expense	-	-	0	-	8
Depreciation	-	-	0	0	-
Income Before Tax	7	-88	-20	-17	-71
Income Tax Expense	0	-	-	-	0
Net Income	8	-88	-20	-17	-70
Net Profit Margin	6.23%	-384.06%	-49.06%	-82.73%	-992.95%

Tvardi Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-4	-30	-20	-12	-7	-4	0
Operating Cash Flow	-5	-30	-12	-13	-4	-4	-8
Investing Cash Flow	-30	25	15	2	5	-	-20
Financing Cash Flow	36	0	0	0	-1	1	22
Change in Cash	-5	-5	2	-10	0	-3	-13

Tvardi Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-88	-20	-17	-70
Operating Cash Flow	-60	-17	-21	-60
Investing Cash Flow	-4	-22	22	48
Financing Cash Flow	46	0	0	-3
Change in Cash	-18	-39	1	-14

Insights on Tvardi Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NEGATIVE IMPACT
Price Dip
In the last 7 days, TVRD stock has moved down by -82.5%

About Tvardi Therapeutics Inc

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Organisation	Tvardi Therapeutics Inc
Headquarters	3 Sugar Creek Center Boulevard, Sugar Land, TX, United States, 77478
CEO	Dr. Imran Alibhai Ph.D.
E-voting on shares	Click here to vote

Key Management of Tvardi Therapeutics Inc

Name	Title
Mr. Wallace Hall	Founder, President & Director
Mr. Dan Conn J.D., M.B.A.	Chief Financial Officer
Dr. John Kauh M.D.	Chief Medical Officer
Mr. David J. Tweardy M.D.	Co-Founder & Scientific Advisory Board Member
Dr. Ronald A. DePinho M.D.	Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael T. Lewis Ph.D.	Co-Founder & Scientific Advisory Board Member
Mr. Stephen O'Brien CPA	VP of Finance & Corporate Controller
Dr. Imran Alibhai Ph.D.	CEO & Director
Dr. Yixin Chen Ph.D.	Vice President of CMC
Dr. Jeffrey Larson DABT, Ph.D.	Senior Vice President of R&D

FAQs

What is Tvardi Therapeutics Inc share price today?

Tvardi Therapeutics Inc share price today is $6.94 as on October 15, 2025 at 1:29 am IST at the close of the market. Tvardi Therapeutics Inc share today touched a day high of $7.12 and a low of $6.15.

What is the 52 week high and 52 week low for Tvardi Therapeutics Inc share?

Tvardi Therapeutics Inc share touched a 52 week high of $43.65 on October 10, 2025 and a 52 week low of $5.65 on October 13, 2025. Tvardi Therapeutics Inc stock price today i.e. October 15, 2025 at 1:29 am IST is closed at $6.94,which is 84.10% down from its 52 week high and 22.83% up from its 52 week low.

What is Tvardi Therapeutics Inc's market capitalisation today?

Tvardi Therapeutics Inc market capitalisation is $0.00T as on October 15, 2025 at 1:29 am IST.

How to invest in Tvardi Therapeutics Inc Stock (TVRD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Tvardi Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tvardi Therapeutics Inc Shares that will get you 0.2161 shares as per Tvardi Therapeutics Inc share price of $6.94 per share as on October 15, 2025 at 1:29 am IST.

What is the minimum amount required to buy Tvardi Therapeutics Inc Stock (TVRD) from India?

Indian investors can start investing in Tvardi Therapeutics Inc (TVRD) shares with as little as ₹88.771 or $1 (as of October 15, 2025 at 3:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹887.71 in Tvardi Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on October 15, 2025 at 3:37 pm IST). Based on Tvardi Therapeutics Inc share’s latest price of $6.94 as on October 15, 2025 at 1:29 am IST, you will get 1.4409 shares of Tvardi Therapeutics Inc. Learn more about fractional shares .